BCI Pharma, in collaboration with Mithra Women’s Health, has demonstrated the anti-tumor activity of its CSF1R inhibitors in several cancer models. Significant tumor regression was observed either alone or in combination with a checkpoint inhibitor leading to a complete sustained tumor regression in 50% of the animals in a triple negative breast cancer model, a very aggressive form of breast cancer. These compelling results demonstrate the huge potential of BCI CSF1R inhibitors in cancer and reinforce the partnership between the two companies.

Follow the link to read Mithra’s press release